Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.

Henk HJ, Cao F, Tuell K, Price K, Singh P, Mardekian J, Odell K, Patel C, Tan W, Sands GH, Singhal S, Trocio J, Vo L.

Curr Med Res Opin. 2018 Mar;34(3):539-546. doi: 10.1080/03007995.2017.1417029. Epub 2018 Jan 10.

PMID:
29235900
2.

The Efficacy of Continuous Versus Intermittent Celecoxib Treatment in Osteoarthritis Patients with Body Mass Index ≥30 and <30 kg/m(2.).

Sands GH, Brown PB, Essex MN.

Open Rheumatol J. 2013 Jul 12;7:32-7. doi: 10.2174/1874312901307010032. Print 2013.

3.

Healthcare resource utilization and economic impact of a ≥2 g/dL decrease in hemoglobin in osteoarthritis patients.

Goldstein JL, Luo X, Cappelleri JC, Sands GH.

J Med Econ. 2013;16(3):430-9. doi: 10.3111/13696998.2013.768529. Epub 2013 Feb 7.

PMID:
23339465
5.

Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR).

Lanas A, Goldstein JL, Chan FK, Wilcox CM, Peura DA, Li C, Sands GH, Scheiman JM.

Aliment Pharmacol Ther. 2012 Sep;36(5):485-92. doi: 10.1111/j.1365-2036.2012.05213.x. Epub 2012 Jul 15.

6.

Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database.

Sands G, Shell B, Zhang R.

Open Rheumatol J. 2012;6:44-9. doi: 10.2174/1874312901206010044. Epub 2012 May 11.

7.

The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.

Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B.

Clin Ther. 2012 Mar;34(3):569-79. doi: 10.1016/j.clinthera.2012.02.001. Epub 2012 Mar 2.

PMID:
22386831
8.

Treatment of osteoarthritis with continuous versus intermittent celecoxib.

Strand V, Simon LS, Dougados M, Sands GH, Bhadra P, Breazna A, Immitt J.

J Rheumatol. 2011 Dec;38(12):2625-34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.

PMID:
22045833
9.

Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.

Goldstein JL, Chan FK, Lanas A, Wilcox CM, Peura D, Sands GH, Berger MF, Nguyen H, Scheiman JM.

Aliment Pharmacol Ther. 2011 Oct;34(7):808-16. doi: 10.1111/j.1365-2036.2011.04790.x. Epub 2011 Aug 2.

11.
12.

Cough, exertional, and other miscellaneous headaches.

Sands GH, Newman L, Lipton R.

Med Clin North Am. 1991 May;75(3):733-47. Review.

PMID:
2020226
13.
14.

Prospective payment experience with DRGs in headache patients.

Sands GH, Mulloy K, Goldstein J, Munoz E.

Headache. 1990 Feb;30(3):157-9.

PMID:
2108935
15.

Neurology, age, hospital costs, and DRGs.

Sands GH, Muñoz E, Gottesman M, Mulloy K, Wise L.

Neurology. 1988 Apr;38(4):655-60.

PMID:
3127741
16.

Wernicke's syndrome: what we don't teach.

Sands GH, Mulloy K.

JAMA. 1987 Nov 13;258(18):2530. No abstract available.

PMID:
3669224
17.

Prescribing oxygen for cluster headaches.

Sands GH.

JAMA. 1986 Dec 26;256(24):3349. No abstract available.

PMID:
3783883
18.

Normal mental state despite bilateral pontine tegmental hemorrhage.

Sands GH, Portenoy RK.

J Neurol. 1986 Aug;233(4):200-1.

PMID:
3746359
19.

Return to alertness after brain-stem hemorrhage. A case with evoked potential and roentgenographic evidence of bilateral tegmental damage.

Portenoy RK, Kurtzberg D, Arezzo JC, Sands GH, Miller A, Vaughan HG Jr.

Arch Neurol. 1985 Jan;42(1):85-8.

PMID:
3966889

Supplemental Content

Loading ...
Support Center